Reduction of myocardial ischemia during percutaneous transluminal coronary angioplasty with oxygenated Fluosol
- PMID: 2195864
- DOI: 10.1016/0002-9149(90)90836-p
Reduction of myocardial ischemia during percutaneous transluminal coronary angioplasty with oxygenated Fluosol
Abstract
The effects of perfusion of an oxygen-carrying perfluorochemical emulsion (Fluosol) in alleviating symptoms of myocardial ischemia during balloon occlusion were examined in a multicenter trial of 245 patients. Severe anginal pain occurred less frequently in patients receiving Fluosol perfusion (21%) than in those receiving routine angioplasty (34%) (p less than 0.05). ST-segment changes at balloon deflation in routine angioplasty patients were significantly greater than in patients who received oxygenated Fluosol perfusion (2.2 +/- 1.2 vs 1.7 +/- 0.9 mm; p less than 0.03). Profound regional wall dysfunction (-561 +/- 224 U) was observed in routine angioplasty patients by 2-dimensional echocardiography. Patients receiving oxygenated Fluosol perfusion, however, maintained near baseline levels of ventricular function (-61 +/- 335 U) during occlusion (p less than 0.0001). Mean global left ventricular ejection fraction was preserved at baseline levels during balloon inflation in patients perfused with oxygenated Fluosol but decreased significantly (p less than 0.001) during occlusion in routine angioplasty patients. A total of 26 complications (19 routine group; 7 perfusion group) was reported. Adverse responses to the perfusate were infrequent, occurring in 1.6 and 2.0% of patients after the test dose and during perfusion, respectively. Thus, transcatheter perfusion with an oxygen-carrying perfluorochemical emulsion is effective in alleviating myocardial ischemia during angioplasty and can be safely administered in this patient population.
Similar articles
-
Perfluorochemical perfusion during coronary angioplasty in unstable and high-risk patients.Circulation. 1990 Mar;81(3 Suppl):IV27-34. Circulation. 1990. PMID: 2306847 Clinical Trial.
-
Prevention of ischemia during percutaneous transluminal coronary angioplasty by transcatheter infusion of oxygenated Fluosol DA 20%.Circulation. 1986 Sep;74(3):555-62. doi: 10.1161/01.cir.74.3.555. Circulation. 1986. PMID: 2943533
-
Protection against ischemia during prolonged balloon inflation by distal coronary perfusion with use of an autoperfusion catheter or Fluosol.J Am Coll Cardiol. 1992 Nov 15;20(6):1378-84. doi: 10.1016/0735-1097(92)90251-h. J Am Coll Cardiol. 1992. PMID: 1430688
-
Protection of the ischemic myocardium during percutaneous transluminal coronary angioplasty.Am J Cardiol. 1988 May 9;61(14):54G-60G. doi: 10.1016/s0002-9149(88)80033-x. Am J Cardiol. 1988. PMID: 2896457 Review.
-
Cardiovascular applications of fluorocarbons: current status and future direction--a critical clinical appraisal.Artif Cells Blood Substit Immobil Biotechnol. 1994;22(4):1083-96. doi: 10.3109/10731199409138804. Artif Cells Blood Substit Immobil Biotechnol. 1994. PMID: 7849911 Review.
Cited by
-
[Artificial oxygen carriers as an alternative to red blood cell transfusion].Anaesthesist. 2005 Aug;54(8):741-54. doi: 10.1007/s00101-005-0893-3. Anaesthesist. 2005. PMID: 16021390 Review. German.
-
Encapsulation and release of Amphotericin B from an ABC triblock fluorous copolymer.Pharm Res. 2012 Jan;29(1):69-82. doi: 10.1007/s11095-011-0511-9. Epub 2011 Jul 8. Pharm Res. 2012. PMID: 21739321 Free PMC article.
-
Phagocytic activation of human neutrophils by the detergent component of fluosol.Am J Pathol. 1992 May;140(5):1081-7. Am J Pathol. 1992. PMID: 1316083 Free PMC article.
-
Nuclear cardiology: the interventionalists' perspective.J Nucl Cardiol. 1994 Jul-Aug;1(4):415-9. doi: 10.1007/BF02939962. J Nucl Cardiol. 1994. PMID: 9420724 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources